Interface(US:TILE)2026-02-24 14:02Financial Data and Key Metrics Changes - In 2025, the company achieved record net sales, adjusted operating income, and adjusted EBITDA, marking the highest levels in its history [4] - Full year net sales totaled $1.39 billion, up 5.4%, with currency-neutral net sales increasing 4.3% [21] - Adjusted gross profit margin increased to 39%, up 187 basis points, driven by favorable pricing and manufacturing efficiencies [22] - Adjusted EPS for the fourth quarter was $0.49, up 44.1% compared to $0.34 [19] Business Line Data and Key Metrics Changes - All three product categories (carpet tile, LVT, and rubber) grew in both price and volume [5] - Global healthcare billings were up 21% year-over-year, with double-digit gains in the Americas and EAAA [14] - Education billings increased 8% for the full year, reflecting the success of expanded collection offerings [15] - Corporate office billings were up slightly for the year, with a focus on gaining share in Class A spaces [15] Market Data and Key Metrics Changes - Currency-neutral net sales in the Americas increased 5.5%, while EAAA saw a 2.4% increase [21] - The company reported a 2% increase in consolidated currency-neutral orders year-over-year [20] - The healthcare and education sectors are experiencing increased investment, driven by aging populations and modernization efforts [15] Company Strategy and Development Direction - The "One Interface" strategy focuses on building strong global functions to support local selling teams and enhancing commercial productivity [4] - The company is committed to sustainability, with initiatives including the launch of a cradle-to-gate carbon negative rubber prototype [12] - The introduction of the noravant product line is expected to open new design possibilities and expand the addressable market [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the scalability of the combined selling team model, particularly in healthcare and education [7] - The company anticipates continued growth in 2026, with a focus on expanding its addressable market through innovative products and pricing strategies [16] - Management acknowledged ongoing macro uncertainties but highlighted a solid order backlog and healthy growth expectations [27] Other Important Information - The company plans to increase capital expenditures to $55 million in 2026 to support automation and productivity initiatives [25] - A quarterly dividend increase from $0.02 to $0.03 per share was approved, reflecting confidence in cash flow generation [26] Q&A Session Summary Question: Can you talk about the One Interface selling strategy? - Management highlighted the success of the combined selling teams, with healthcare billings up 21% and expectations for continued growth through the launch of noravant [35][36] Question: Can you discuss gross margins for 2026? - Management noted that gross margins achieved 38.5%, with expectations for continued expansion driven by automation and efficiency initiatives [38][39] Question: What is the outlook for the corporate market? - Management indicated that the corporate market remains competitive, with growth expectations aligned with strong demand in Class A spaces [48] Question: Can you elaborate on the backlog increase? - Management described the backlog as solid and well-distributed across various initiatives, providing confidence for entering 2026 [51][53] Question: How is the company managing SG&A expenses? - Management emphasized a disciplined approach to SG&A, focusing on investments that drive growth while maintaining efficiency [56][57] Question: What is the impact of tariffs on gross margins? - Management indicated that tariffs had a dilutive impact on gross profit percentage, with expectations for modest inflation in raw materials [95][96]